Cargando…
Immunophenotypes associated with bipolar disorder and lithium treatment
Immune dysfunction is implicated in the etiology of bipolar disorder. The single-nucleotide polymorphism rs17026688 in the gene encoding glutamate decarboxylase–like protein 1 (GADL1) has been found to be associated with lithium response in Han Chinese patients with bipolar I disorder (BDI). However...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877517/ https://www.ncbi.nlm.nih.gov/pubmed/31767892 http://dx.doi.org/10.1038/s41598-019-53745-7 |
_version_ | 1783473347110109184 |
---|---|
author | Wu, Tai-Na Lee, Chau-Shoun Wu, Bo-Jian Sun, Hsiao-Ju Chang, Chieh-Hsing Chen, Chun-Ying Chen, Chih-Ken Wu, Lawrence Shih-Hsin Cheng, Andrew Tai-Ann |
author_facet | Wu, Tai-Na Lee, Chau-Shoun Wu, Bo-Jian Sun, Hsiao-Ju Chang, Chieh-Hsing Chen, Chun-Ying Chen, Chih-Ken Wu, Lawrence Shih-Hsin Cheng, Andrew Tai-Ann |
author_sort | Wu, Tai-Na |
collection | PubMed |
description | Immune dysfunction is implicated in the etiology of bipolar disorder. The single-nucleotide polymorphism rs17026688 in the gene encoding glutamate decarboxylase–like protein 1 (GADL1) has been found to be associated with lithium response in Han Chinese patients with bipolar I disorder (BDI). However, whether patients with GADL1 polymorphisms have different immunophenotypes is unknown. To address this issue, differences in the immune profiles based on analysis of peripheral blood mononuclear cells (PBMCs) were compared among BDI patients and healthy controls who lack or carry the T allele of rs17026688. BDI patients had significantly higher percentages of total T cells, CD4(+) T cells, activated B cells, and monocytes than healthy controls, suggesting that immunologic imbalance might be involved in BDI development or progression. Treatment of BDI patients-derived PBMCs with lithium in vitro increased the percentage of CD14(+) monocytes and dendritic cells, suggesting that lithium plays an immunomodulatory role in CD14(+) monocytes and dendritic cells. Among BDI patients, non-T carriers had a significantly higher percentage of CD11b(+)/CD33(lo)/HLA-DR(−) myeloid-derived suppressor cells than T carriers. Moreover, only T carriers exhibited differential sensitivity to lithium therapeutic use with respect to the percentage of myeloid cells. These findings suggest that rs17026688 polymorphisms in GADL1 are associated with immune dysfunction in BDI patients. |
format | Online Article Text |
id | pubmed-6877517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-68775172019-12-05 Immunophenotypes associated with bipolar disorder and lithium treatment Wu, Tai-Na Lee, Chau-Shoun Wu, Bo-Jian Sun, Hsiao-Ju Chang, Chieh-Hsing Chen, Chun-Ying Chen, Chih-Ken Wu, Lawrence Shih-Hsin Cheng, Andrew Tai-Ann Sci Rep Article Immune dysfunction is implicated in the etiology of bipolar disorder. The single-nucleotide polymorphism rs17026688 in the gene encoding glutamate decarboxylase–like protein 1 (GADL1) has been found to be associated with lithium response in Han Chinese patients with bipolar I disorder (BDI). However, whether patients with GADL1 polymorphisms have different immunophenotypes is unknown. To address this issue, differences in the immune profiles based on analysis of peripheral blood mononuclear cells (PBMCs) were compared among BDI patients and healthy controls who lack or carry the T allele of rs17026688. BDI patients had significantly higher percentages of total T cells, CD4(+) T cells, activated B cells, and monocytes than healthy controls, suggesting that immunologic imbalance might be involved in BDI development or progression. Treatment of BDI patients-derived PBMCs with lithium in vitro increased the percentage of CD14(+) monocytes and dendritic cells, suggesting that lithium plays an immunomodulatory role in CD14(+) monocytes and dendritic cells. Among BDI patients, non-T carriers had a significantly higher percentage of CD11b(+)/CD33(lo)/HLA-DR(−) myeloid-derived suppressor cells than T carriers. Moreover, only T carriers exhibited differential sensitivity to lithium therapeutic use with respect to the percentage of myeloid cells. These findings suggest that rs17026688 polymorphisms in GADL1 are associated with immune dysfunction in BDI patients. Nature Publishing Group UK 2019-11-25 /pmc/articles/PMC6877517/ /pubmed/31767892 http://dx.doi.org/10.1038/s41598-019-53745-7 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Wu, Tai-Na Lee, Chau-Shoun Wu, Bo-Jian Sun, Hsiao-Ju Chang, Chieh-Hsing Chen, Chun-Ying Chen, Chih-Ken Wu, Lawrence Shih-Hsin Cheng, Andrew Tai-Ann Immunophenotypes associated with bipolar disorder and lithium treatment |
title | Immunophenotypes associated with bipolar disorder and lithium treatment |
title_full | Immunophenotypes associated with bipolar disorder and lithium treatment |
title_fullStr | Immunophenotypes associated with bipolar disorder and lithium treatment |
title_full_unstemmed | Immunophenotypes associated with bipolar disorder and lithium treatment |
title_short | Immunophenotypes associated with bipolar disorder and lithium treatment |
title_sort | immunophenotypes associated with bipolar disorder and lithium treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877517/ https://www.ncbi.nlm.nih.gov/pubmed/31767892 http://dx.doi.org/10.1038/s41598-019-53745-7 |
work_keys_str_mv | AT wutaina immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT leechaushoun immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT wubojian immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT sunhsiaoju immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT changchiehhsing immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT chenchunying immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT chenchihken immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT wulawrenceshihhsin immunophenotypesassociatedwithbipolardisorderandlithiumtreatment AT chengandrewtaiann immunophenotypesassociatedwithbipolardisorderandlithiumtreatment |